The downside of downsizing: playing it safe

"Gone are the people who acquired the experience to know what doesn't work... Those with sufficient boldness to try something outside the conventional axioms now spend their mornings expanding their LinkedIn contacts," laments Daniel Hoffman, president at Pharmaceutical Business Research Associates, in Pharmalot. The result? Politically savvy, play-it-safe employees, those least likely to drive the changes needed to get pharma growing again. Op-Ed

Suggested Articles

Hospital-backed Civica Rx has struck a deal for a CDMO to help it develop its own brand of drugs, for which it will own the rights.

South Korea’s Celltrion, which has a massive biologics site in Songdo, has decided it is time to build some operations in China.

WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.